Neutral Cipla; target of Rs 1450: Motilal Oswal

Moneycontrol • 4 days ago

Original source

Key Investment Pillars

  • Cipla's North America sales are expected to improve, driven by the scale-up of respiratory and peptide products, with a target of achieving a sales run rate of USD250m from 4QFY27 onward.
  • The company's domestic business is expected to sustain growth momentum, driven by strong execution in chronic therapies and new product launches.
  • Cipla's consumer health business is expected to deliver double-digit growth, supported by underlying demand and mitigation of cost and pricing headwinds.
  • The company's One Africa business is expected to deliver 5.5% CAGR over FY26-28, driven by continued private market share gains in South Africa and stable growth across markets.

Thesis Validation Checklist

  • Monitor the ramp-up of Cipla's North America portfolio, particularly the scale-up of respiratory and peptide products.
  • Track the company's domestic business growth, driven by chronic therapies and new product launches.
  • Watch for the performance of Cipla's consumer health business, including its ability to deliver double-digit growth.
  • Keep an eye on the company's One Africa business, including its private market share gains in South Africa and growth across markets.